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Abstract 
 
In the last 3 years de novo sequence variants in the ARID2 (AT-rich interaction domain 2) 
gene, a subunit of the SWI/SNF complex, have been linked to intellectual disabilities in 3 
case reports including one which describes frameshift mutations in ARID2 in 2 patients with 
features resembling Coffin-Siris syndrome.  
ARID2-related intellectual disability is characterised by coarse facial features, intellectual 
disability, hypotonia, behavioural problems and hypoplasia of the fifth finger or toe nails. 
There is a significant overlap with clinical features apparent in Coffin-Siris syndrome. Coffin-
Siris syndrome (CSS) is a rare congenital syndrome characterized by intellectual deficit, 
coarse facial features and hypoplastic or absent fifth fingernails and/ or toenails among other 
features. Mutations in a number of different genes encoding SWI/SNF chromatin remodelling 
complex proteins have been described but the underlying molecular cause remains unknown 
in approximately 40% of patients with CSS. 
Here we describe 7 unrelated individuals, 2 with deletions of the ARID2 region and 5 with de 
novo truncating mutations in the ARID2 gene. Similarities to CSS are evident. Although 
hypertrichosis and hypoplasia of the fifth finger nail and distal phalanx do not appear to be 
common in these patients, toenail hypoplasia and the presence of Wormian bones might 
support the involvement of ARID2.  
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Introduction 
The AT-rich interaction domain 2 (ARID2) protein is a subunit of the SWI/SNF chromatin 
remodelling complex and is involved in transcriptional activation and repression of target 
genes[1] [2]. There are two major subfamilies of the complex: BAF (BRG1- or hBRM-
associated factor) and PBAF (polybromo-associated factor) and ARID2 is a component of 
the latter. ARID2 is required for the stability of the SWI/SNF complex that catalyses 
nucleosome repositioning [PMID: 10466730] and enables DNA to be accessed by 
transcription factors and repair enzymes. [3] The ARID2 protein is highly expressed in the 
heart, stomach, oesophagus, fetal testis and fetal brain [4]. ARID2 interacts with several 
other subunits of the BAF complex such as SMARCE1, SMARCA4 and SMARCB1 [4, 5], all 
of which are implicated in Coffin Siris Syndrome (CSS). [6]   
Coffin-Siris syndrome (CSS, OMIM: #135900) is a heterogeneous congenital anomaly 
syndrome characterized by intellectual disability, hypertrichosis, coarse facial appearance, 
sparse scalp hair, and hypoplastic or absent fifth fingernails or toenails. Other features may 
include feeding difficulties, poor growth, craniofacial abnormalities, spinal anomalies, and 
congenital heart defects. The ARID1B gene is most commonly associated with CSS and 
approximately 37% of patients harbour pathogenic mutations [7] within this gene. Loss of 
function mutations including microdeletions, nonsense variants, and frameshifts have all 
been described [6, 8-15]  but no clearly pathogenic missense variants have been identified. 
As well as other genes encoding proteins of the SWI/SNF complex mentioned above, 
mutations in the SOX11 gene have been described recently in patients with features 
resembling CSS. SOX11 is also involved in regulation of transcription and acts downstream 
from the PAX6-BAF complex [16, 17]  
Using whole exome sequencing (WES), Shang et al [18] identified four independent, novel, 
loss of function variants in ARID2 gene in four patients, three of which were confirmed to be 
de novo while parental samples were not available for the fourth patient. All four of these 
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patients have intellectual disability and share other characteristics including attention deficit 
hyperactivity disorder, short stature, dysmorphic features and Wormian bones. More recently 
Bramswig et al [19] described 2 individuals with ARID2 mutations and CSS-like phenotypes 
and Van Paemel et al [20] reported a case with partial deletion of the ARID2 gene and 
significant phenotypic overlap with CSS. 
Here we describe 7 additional unrelated individuals with mutations in or involving the ARID2 
gene and compare their findings to features considered to be typical of CSS whilst 
highlighting possible differentiating features. 
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Materials and methods 
Patient selection & data acquisition 
The UK-wide Deciphering Developmental Disorders (DDD) Study has collected DNA 
samples and phenotype information from 13632 children and adults over a 4 year period 
from April 2011. These individuals presented with an undiagnosed developmental disorder to 
24 Regional Genetics Services in the UK and Republic of Ireland participating in patient 
recruitment. The primary aim of the DDD study has been to identify the underlying molecular 
diagnosis by performing SNP array comparative genomic hybridisation (array CGH, also 
known as chromosomal microarray) and exome sequencing on the samples obtained from 
family trios [21]. The DDD study has also compiled a carefully curated list of genes reported 
to be associated with developmental disorders: the DDG2P (Developmental Disorders 
Genotype-to-Phenotype) database [22]. As ARID2 has only recently been identified as a 
potential developmental gene it was not included in the DDG2P database at the time of data 
collection for this paper.  
A request was made via a Complementary Analysis Project (www.ddduk.org ) to access 
data from the first 4,293 trios sequenced and 5 DDD recruits were found to possess a 
protein-truncating variant within the ARID2 gene. Patient 1 was identified by chromosomal 
microarray carried out as part of a screen for developmental delay while patient 7 was found 
and included in our cohort after performing a copy number variant overlap search on the 
DECIPHER website. DECIPHER is a secure online portal that contains a database of 
genetic and phenotypic data for patients with copy number and other genetic variants 
submitted by contributors worldwide. All genomic and phenotype data collected by the DDD 
Study are also held securely within this database. Additional clinical data were obtained by 
contacting Clinical Geneticists who recruited patients to the DDD study and the DECIPHER 
database. Consent for publication was obtained from all patients or legal guardians locally. 
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Array CGH 
Array CGH on patients 1 and 7 were carried out using OCG 8*60K ISCA v2.0 and BlueGnome 
Cytochip 8x60 K v2.0 oligonucleotide arrays respectively.  This was analysed using 
BlueFuse Multi v2.5 (9271), CytoChip v2 algorithm. Coordinates refer to human genome 
build GRCh37 (hg19).  Fluorescence in situ hybridisation (FISH) using BAC probes 
(BlueGnome BlueFish) was used to confirm gains and losses detected by array-CGH and to 
test parents to confirm that the copy number variant had arisen de novo in the proband. Both 
copy number variants (CNVs) are recorded in the DECIPHER database 
[https://decipher.sanger.ac.uk; Decipher ID numbers: 284808 (patient 1) and 267546 (patient 
7)]. 
Exome sequencing 
Five DDD Study participants underwent whole exome sequencing (WES) of family trios, 
consisting of an affected individual/proband and the unaffected parents. Trio analysis allows 
detection of de novo mutations predicted to be functionally significant, as described 
previously (Wright et al, 2015). Sequencing was performed using Agilent SureSelect 55MB 
Exome Plus with Illumina HiSeq technology. De novo variants were identified by the 
DeNovoGear program and single nucleotide variants (SNVs) annotated by variant effect 
predictor (VEP) software of the Ensembl database (http://www.ensembl.org/Tools/VEP). The 
variants are publicly available in the DECIPHER database 
(https://decipher.sanger.ac.uk/gene/ARID2#variants ). 
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Results 
Patient 1  
Phenotype 
Patient 1 was referred to the Clinical Genetics Service regarding his growth and 
development. He was born by an emergency caesarean section for placenta previa at term 
with a birth weight of 2.296kg (-4.0 SD).  He had had laryngomalacia which required surgical 
correction and there was a history of feeding difficulty, vomiting in early infancy, constipation 
and sleep disturbance. He was moderately delayed on developmental assessment (walked 
at 20 months of age and said his first words at the age of 19 months). He was short (87.8 
cm, -3.6 SD) with a normal head circumference (-0.05 SD) and dysmorphic features 
including thin upper lip, micrognathia and low set ears were described. His toenails were 
noted to be hypoplastic.  (Figure 1 and Table 1).  
Genotype 
Array CGH revealed male pattern with a heterozygous loss of 246,499bp deletion at 12q12, 
location 46,013,532 to 46,260,030 bp (GRCh37/hg19) encompassing the ARID2 gene only. 
(Figure 2 and Table 1) 
 
Patient 2  
Phenotype 
Fetal scans identified renal pelvis dilatation and polyhydramnios. He was born at term 
weighing 3300g (-0.53 SD).  He presented in infancy with severe feeding difficulties and 
developmental delay: he smiled at 12 weeks, sat at 15 months and walked independently at 
21 months. He was assessed at the age of 2 years when he was speaking with single words 
but mainly communicating non-verbally. His height was 82 cm (- 2.4 SD), weight 12.2 kg (-
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0.3 SD) and OFC 50.7 cm (+0.3 SD). He has suffered from constipation and frequent 
infections during infancy. He exhibited generalised hypotonia and joint hypermobility with 
mildly elevated creatine kinase levels and myotonic dystrophy (DM1) was subsequently 
ruled out. On examination he had plagiocephaly, protruding ears, thin upper lip vermilion and 
downturned corners of the mouth. Array CGH was normal. (Figure 1 and Table 1) 
Genotype 
A heterozygous de novo frameshift mutation in exon 10 of the ARID2 gene was detected by 
exome sequencing [12:g.46231317_46231318insT (GRCh37/hg19); NM_152641.2 
(ARID2_v001):c.1158dup; NP_689854.2: p. (Asn387*)]. (Figure 3 and Table 1) 
 
Patient 3  
Phenotype 
Patient 3 was born at term with a birthweight of 3129g (-1.0 SD) and OFC 36 cm (+1.0 SD). 
Other than having a raised alphafetoprotein (AFP) level, the pregnancy was uncomplicated. 
He was referred to clinical genetics at 6 months for assessment of disproportionate growth 
parameters and developmental delay. Cranial ultrasound was normal. At 2 years of age he 
weighed 12 kg (-0.89 SD), his height was 83 cm (-2.06 SD) and OFC 52.8 cm (+2.0 SD). He 
was classed as moderately delayed in all areas of development: he smiled at 16 weeks, sat 
independently at the age of 10 months and walked between the ages 2 and 2.5 years. He 
started speaking in sentences at about the age of 5 years and he has a stammer. He is able 
to follow single stage commands, prefers routine and has a limited range of interests. He 
attends a special educational needs school with some time in a mainstream school with one 
to one assistance. He is sensitive to loud noises and crowds. On examination at 6 years 10 
months his height was 114.5cm (-2.0 SD), 20.85kg (-1.0 SD) and OFC 55.5cm (+2.0 SD) 
demonstrating relative macrocephaly. He has a high broad forehead with down-slanting 
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palpebral fissures and slightly low-set posteriorly rotated ears. He has an alternating 
strabismus but satisfactory vision. His fingernails are normal but all toenails, especially digits 
3, 4 and 5 are hypoplastic. MRI scan of his cranium at the age of 6 months demonstrated a 
mildly dysmorphic corpus callosum (curved with a thin elongated splenium) and delayed 
myelination (equivalent to 4 months). The local Geneticist performed Genetic investigations 
prior to recruitment into the DDD Study. These included testing for PTEN mutation and a 
RASopathy panel, which did not identify any variants. (Table 1 and Figure 1)  
Genotype 
A heterozygous de novo stop gained variant was found in exon 4 of the ARID2 gene [12: 
g.46205315 C>G (GRCh37/hg19); NM_152641.2: c.399C>G; NP_689854.2: p. (Tyr133*)]. 
This patient was also found to have compound heterozygous missense variants in the VDR 
gene [12: g.48238711 C>T; NM_001017536.1:c.1252C>T; NP_001017536.1:p.(Arg418Cys) 
and 12:g.48272629 G>A; NM_001017536.1:c.296+122C>T]. The patient does not exhibit 
any features of rickets, the phenotype associated with this gene and the variants were 
classed as likely benign and benign respectively. (Figure 3 and Table 1) 
 
Patient 4  
Phenotype 
Patient 4 was identified through the DDD Study. He was born at term to non-
consanguineous parents weighing 3630 grams (+0.16 SD). Increased nuchal translucency 
was detected on the antenatal ultrasound scans during pregnancy. Significant speech and 
global developmental delays were noticed during early childhood and his behaviour was 
described as rigid with physical outbursts and high anxiety levels. He smiled at 14 weeks, 
sat independently at 8 months and walked unaided at the age of 2-2.5 years. He said his first 
words over the age of 5 years and is currently being assessed for autistic spectrum disorder.  
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Assessment at the age of 8 years revealed short stature with height 122.1cm (-1.37 SD), 
weight 30.85 kg (+0.94 SD) and head circumference 55cm (+0.65 SD) and on physical 
examination he was found to have micrognathia, webbed neck, hypoplastic fingernails and 
short toes. Differential diagnoses of Noonan syndrome, Pallister-Killian syndrome and Smith-
Lemli-Opitz syndrome were considered but genetic investigations including karyotype, 
telomere screen, FISH of 12p on buccal swab and array CGH were reported as normal. 
Skeletal survey was suggestive of multiple epiphyseal dysplasia and skull X-ray showed 
Wormian bones. (Figure 1 and Table 1) 
Genotype 
Whole exome sequencing revealed a heterozygous de novo stop gained mutation in ARID2 
gene in exon 15, at position 4624350 substituting a cytosine by thymine [12: g.46246350 
C>T (GRCh37/hg19); NM_152641.2: c.4444C>T; NP_689854.2: p. (Gln1482*)]. The base 
change at this position results in a premature stop codon and truncation of the protein. 
(Figure 3 and Table 1) 
 
Patient 5  
Phenotype 
Patient 5 was born at 38 weeks gestation weighing 2891g (-2.2 SD); his length was 53 cm (-
2 SD) at 6 weeks. His mother reported decreased fetal movements and developed 
polyhydramnios. He was slow to feed in infancy owing to his poor swallow. He sat 
independently at age 10 months, walked at 2 years, required speech and language therapy 
(SALT) input from age 2 years and was able to speak in full sentences by the end of primary 
school. He attended mainstream school with support. He wears glasses for a combination of 
myopia and hypermetropia. When assessed by clinical genetics he was found to be short 
with height following the 0.4th centile. Dysmorphic features included thick eyebrows, ptosis, 
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prominent eyelashes, flat nasal bridge, short nose, broad nasal root and tip, anteverted 
nares, thick alae nasi, broad philtrum, high and broad forehead and slightly posteriorly 
rotated ears. In addition he was observed to have mild 5th finger clinodactyly and small nails 
on his 2nd toes which are flexed and curled under at the distal phalangeal joints. Mild joint 
laxity was also noted. (Figure 1 and Table 1) 
Genotype 
A heterozygous de novo frameshift mutation was detected in exon 15 of the ARID2 gene 
[12: g.46246590_46246591insCAAG (GRCh37/hg19); NM_152641.2: c.4687_4690dup; 
NP_689854.2: p. (Thr1564Lysfs*5)]. (Figure 3 and Table 1) A maternally inherited missense 
variant (X: g.5447558 C>T, NM_004463: c.2269G>A) in the FGD1 gene was also identified 
by the DDD Study but this was classed as a variant of uncertain significance (VUS). 
 
Patient 6  
Phenotype 
Patient 6 was born at term to non-consanguineous parents. His birth weight was 3000 grams 
(-1.16 SD). He was able to walk independently at the age of 12 months but only started 
speaking over the age of 5 years. He attended special needs nursery and school.  As an 
adult, he is able to speak in sentences but mainly uses single words and phrases and is 
functioning at the level of a 5 year old, having recently learned to write his name.  
When assessed at age 18 years, his height was 182.2 cm (+0.74 SD), weight 83.2 kg (+1.5 
SD) and OFC 57.3 cm (+0.04 SD). He was dysmorphic with coarse face, low anterior 
hairline, thick eyebrows, broad nasal tip, thick vermilion of the lower lip and micrognathia 
(Figure 1 Patient 6). He has pes cavus, joint hypermobility and myopia. Genetic testing for 
Fragile X syndrome was reported as negative. (Figure 1 and Table 1) 
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Genotype 
Whole exome sequencing identified a heterozygous de novo frameshift mutation at position 
12: 46244551 in exon 15 of ARID2, GCT replacing a G at this position 
[12:g.46244551_46244552, G>GCT (GRCh37/hg19); NM_152641.2: c.2645_2646insCT; 
NP_689854.2: p. (Val883Leufs*10)]. (Figure 3 and Table 1) 
 
Patient 7  
Phenotype 
Patient 7 was born at 42 weeks gestation weighing 3062 grams (-2.0 SD) and was noted to 
have stridor from birth. She was seen in the genetics clinic on account of her short stature 
and moderate learning difficulties and on assessment she was dysmorphic with 
downslanting palpebral fissures, low-set and posteriorly rotated ears, narrow and high 
palate, small chin and arachnodactyly. All toenails were hypoplastic. Generalised hypotonia 
was noted during infancy. Skeletal features comprising mild pectus carinatum, 
hyperkyphosis of the thoracic spine and hyperlordosis of the lumbar spine were also 
reported (Table 1). At the age of 6 months she required surgery for a laryngeal web. She 
went into puberty aged 16 years and although her stature was short through childhood her 
final adult height is 161.5 cm (-1 SD) and OFC 55cm (-0.5 SD).She suffered cerebral sinus 
thrombosis aged 22 and was investigated for homocystinuria although this was excluded. 
She is also reported to have anxiety. (Figure 1 and Table 1) 
Genotype 
Array CGH revealed a heterozygous 1.39 Mb deletion at 12q12-13.11 [12: 46189641 to 
47575801, GRCh37/hg19] involving 7 protein coding genes including ARID2. The other 
genes (AMIGO2, PCED1B, SCAF11, SLC38A1, SLC38A2, SLC38A4) are not listed by 
DECIPHER as morbid and do not appear in the DDG2P database. (Figure 2 and Table 1) 
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In addition, this patient was also noted to have heterozygous 329.66 kb duplication at 
7q11.23 (7: 75255680-75585337). The duplication was also detected in one of his 
unaffected parents and therefore was classed as benign. (Figure 2 and Table 1) 
  
16 
 
Discussion 
The ARID2 gene encodes one of the DNA-binding proteins characterized by an AT-rich 
interactive domain. Members of the ARID family have been described to play a role in 
embryonic patterning, cell lineage gene regulation, the control of cell cycle and regulating the 
transcription and modification of chromatin structure [1-3]. The ARID2 protein functions as 
one of the unique subunits of the polybromo- and BRG1-associated factor (PBAF) protein 
subset within the SWI/SNF chromatin remodelling complex [23] and is expressed in all 
tissues [4].  
Pathogenic variants in other members of the SWI/SNF chromatin remodelling complex, 
namely ARID1B, SMARCA2, ARID1A, SMARCB1 and SMARCE1, have been reported in 
individuals with CSS [8, 11, 13, 24] while ARID1B variants have also been reported in non-
syndromic intellectual disability with or without hypoplasia of the corpus callosum [6]. Shang 
et al [18] previously reported 4 unrelated individuals who possess likely pathogenic variants 
in ARID2, all of them sharing characteristics that included intellectual disability, hypotonia, 
short stature, failure to thrive and dysmorphic features: micro/retrognathia, downslanted 
palpebral fissures, frontal bossing and low set and posteriorly rotated ears. Patient 4 (S4 in 
Table 1) was reported to have an additional de novo variant in the EP300 gene but she did 
not resemble features typical of Rubinstein-Taybi syndrome. More recently Bramswig et al. 
[19] reported two individuals with de novo frameshift ARID2 variants and a phenotype 
resembling Coffin Siris syndrome. These patients have similar facial features to those 
described by Shang et al. Individual 1 in Bramswig’s paper developed seizures from age 14 
months. Although seizures are described in a proportion of cases with CSS [25], the finding 
of a de novo variant in TRIM8 could also account for his seizures and be contributing to his 
severe intellectual disability.  
Comparing the 7 patients presented in this paper with those previously reported (see table), 
all have a degree of developmental delay ranging from moderate to severe, which would be 
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in keeping with a diagnosis of CSS [25]. All 7 patients presented here were delayed in 
speech acquisition with 3 said to have had no words until after 5 years. The younger patient 
reported by Bramswig was using signs when assessed at 4.5 years while the second patient 
with a possible second pathogenic variant had no speech at 7 years. Three out of 7 cases 
were small for gestational age, which is similar to the proportion of CSS cases in other series 
with this finding [6]. Short stature (5th centile or less) is common in CSS and was present in 
10 of 14 and none of the children assessed had heights above -1 standard deviation for their 
age. Head circumferences were all around the mean for age apart from patient 3 who has 
relative macrocephaly. We do not have information about growth during childhood for patient 
6 who was assessed as a young adult but patient 7 had been small throughout childhood but 
achieved a normal adult height after late onset of puberty. Interestingly, the combination of 
short stature and dysmorphic features led to 2 patients being tested for Noonan syndrome 
and other RASopathies. 
Before the identification of ARID1B and other genes associated with CSS, clinical diagnosis 
of this syndrome was always relatively difficult as the facial gestalt is not as well defined as 
in other syndromes and there was debate whether all patients diagnosed with CSS had the 
same diagnosis [8]. Hypoplasia of the distal phalanx and nail of the fifth finger is highly 
indicative but is not always present. Although Bramswig et al. described this sign in both of 
their cases, this feature was not apparent in the 7 cases described here, however toenail 
hypoplasia was marked in 4/7 and this has also been described in CSS. Other ectodermal 
features associated with CSS are less specific and include hypertrichosis and sparse scalp 
hair. None of our 7 cases were documented as having these findings. One feature not 
commented on previously but noticeable in this series and in published photographs of other 
ARID2 cases is that almost all cases appear to have blonde hair and none have very dark 
coloured hair. This is possibly coincidental and simply a reflection of their ethnicity and it will 
be interesting to see if it is borne out when more cases are identified. 
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Individuals with CSS are said to have coarse facial features comprising bushy eyebrows, 
broad nasal tip and thickened alae nasi and lower lip vermilion. This tends to become more 
apparent with time. In our opinion, the younger patients in our cohort do not have this 
appearance but there is the impression of gradual coarsening in those patients over 5 years. 
This is also evident in pictures of patients 2 and 3 published by Shang et al, quite 
dramatically in the picture of individual 1 in the Bramswig paper and less markedly in 
individual 2 in the Bramswig paper and in photos of the patient presented by Van Paemel et 
al. All 7 patients presented here have similarities in facial appearance and these are also 
present in the photographs of 4 patients included in previous case series. Tall broad 
forehead, micro/retrognathia, downslanting palpebral fissures, low set and posteriorly rotated 
ears, and relatively short nose and long philtrum are consistent (Figure 1) and described in 
the previous case reports. On reviewing published pictures, other similarities are pronounced 
cupid’s bow configuration of the upper lip vermilion in association with prominent philtral 
pillars in some cases while others have a wide mouth and broad shallow philtrum. In almost 
all cases the corners of the mouth appear down-turned. There is also relative malar 
hypoplasia with associated infraorbital fullness.   
Behavioural phenotypes were described in 4 of the 7 patients ranging from anxiety, sleep 
disturbance, sensitivity to loud noises, ‘routine driven’ or rigid behaviour and physical 
outbursts, to being quiet and inappropriately affectionate. Aggressive behaviour, anxiety, tics 
and attention deficit disorder were also described by Shang et al. and hyperactivity and short 
attention span by Van Paemel et al. Therefore, behavioural issues appear to be a common 
problem. Other frequently reported but less specific findings are generalised hypotonia, joint 
hypermobility, feeding difficulties and a tendency to constipation. Of note, 2 patients required 
surgery for laryngeal anomalies. Skeletal anomalies including chest deformity, kyphosis and 
kyphoscoliosis are described in 4 of 14 patients while another was thought to have possible 
skeletal dysplasia. The presence of Wormian bones documented in 3 of 14 patients is 
intriguing and might be a useful diagnostic clue. Wormian bones are more often seen in 
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primary skeletal dysplasias and osteogenesis imperfecta and we speculate that ARID2, part 
of the SWI/SNF chromatin remodelling complex, might have an influence on the BMP 
pathway and bone formation. Mutations in the protease domain of Bone morphogenetic 
protein 1 (BMP1), a member of the BMP signalling pathway, have been reported in 
individuals with osteogenesis imperfecta which is characterised by the presence of Wormian 
bones [26]. In an analysis of stable ARID2 knockdown cells, Xu et al. demonstrated that 
ARID2-containing complexes play a critical role in normal osteoblast differentiation and in 
the regulation of expression of at least BMP4 and FGFR2 genes [23].  While a previous 
study, using BRG1 mutant cells, determined that the SWI/SNF chromatin remodelling 
complex is required for the BMP2-induced skeletal gene expression that controls osteoblast 
differentiation [27]. Bone morphogenetic protein (BMP) signalling has been shown to 
influence many processes in early development including cell growth, apoptosis and 
differentiation [28-30] and it is extensively regulated by various extracellular, intracellular and 
membrane modulators [31]  
Patient 1 and 7 both have partial deletions of the ARID2 gene whereas patients 2-6 were 
found to have truncating (frameshift and stop gained) mutations suggesting that 
haploinsufficiency of the ARID2 gene through a loss of function mechanism is the likely 
molecular cause for these patients’ phenotypes. This is also suggested by the types of 
mutations previously reported in the literature.[18, 19].  
Although at the present time, approximately 40% of the individuals with CSS-like features do 
not receive a molecular diagnosis [10-12, 32], features in our patients overlap sufficiently to 
suggest that ARID2 mutations could account for a proportion of these. 
In summary, this case series brings to a total of 14 unrelated patients with disruption of the 
ARID2 gene resulting in phenotypic features overlapping with those described in CSS. 
Intellectual disability, short stature, hypoplastic toe or fingernails with characteristic facial 
features which become more apparent with age are all in keeping with this diagnosis. The 
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presence of Wormian bones, skeletal and laryngeal anomalies appear to be additional 
findings while common non-specific findings such as feeding difficulties, constipation, joint 
laxity and refraction errors contribute to the morbidity associated with this disorder. Though 
less commonly associated with CSS, macrocephaly, seizures and non-verbal severe 
intellectual disability are all reported in single cases here and could be part of the spectrum 
or, alternatively, be due to a second disorder affecting these patients.  
This case series provides further evidence that ARID2 is a developmental gene associated 
with intellectual disability and further supports the contention raised by Braumswig et al, that 
disruption of the ARID2 gene causes a Coffin-Siris like phenotype in affected individuals.  
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Figure legends 
 Figure 1. Patients 1-7, showing facial phenotypes in the upper panel, profiles in middle panel and limb phenotypes in lower 
panel.   
Figure 2. Genomic location of deletions found in patients 1 and 2, indicated as red horizontal bars. 
Figure 3. Schematic of ARID2 mutations; stop gained variants are indicated by red arrows and frameshift variants by black 
arrows, respectively. Diagram extracted from the DECIPHER website. 
(https://decipher.sanger.ac.uk/gene/ARID2#overview/protein-info) 
 
 
 
Table 1. Clinical features and genotypes of patients carrying ARID2 mutations. 
 
ID P1 
Decipher284808 
P2 
DDD 267395 
P3 
DDD 275526 
P4 
DDD 263830 
P5 
DDD 265539 
P6 
DDD 272339 
P7 
Decipher267546 
S1 S2 S3 S4 B1 B2 VP 
ARID2 variant  deletion exons 1-16  c.1158dup;  
p. (Asn387*)  
c.399C>G; 
p. (Tyr133*) 
c.4444C>T;  
p. (Gln1482*) 
c.4687_4690dup; 
p.(Thr1564Lysfs*5)  
c.2645_2646insCT; 
p.(Val883Leufs*10) 
Deletion exons 4-
21 
c.2536delG; 
p.Val846Leufs*
3 
c.1028 T>A; 
p.Leu343* 
c.4441delC; 
p.His1481Ilefs*
4 
c.4318 C>T; 
p.Q1440* 
c.3411_3412de
lAG; 
p.Gly1139Serfs
*20 
c.156delC; 
p.Arg53Glufs
*5 
Deletion 
exons 3-5 
Age/Gender 4.5y/M 5y/M 7y/M 8.3y/M 15.5y/M 18y/M 23y/F 15y/F 8y/F 6y/M 8y/F 7y/M 4y/M 3.9 y/F 
Pregnancy Placenta previa PH 
Dec FM 
Raised AFP Increased NT PH 
Dec FM 
      Two previous 
miscarriages, 
born at 36 
weeks 
PH,Short 
femur (3rd 
centile) on 
antenatal 
scans 
IUGR 
Placental 
calcifications 
BW SD -3sd -0.53sd -1sd +0.16sd -2.2sd -1.16sd -2sd -2sd -1sd -1sd -1sd -1.6sd +2.1sd -1.4sd 
Height/OFC  SD -3.6/-0.05 -2/+0.3 -2.06/+2 -1.37/+0.65 -2/nk +0.74/+0.04 -1/-0.5 -2.5/nk -1/nk -2/nk -2.5 -2.14/+0.68 -2.2/-0.4 -3.3/-2.0 
Intellectual 
impairment 
mod mod mod + + + mod + + + + + + + 
First words 
spoken 
19m 2y 5y >5y 2y >5y nk 1 y nk 18m nk absent absent 2y 
Behaviour Sleep disturbance ‘Routine driven’ 
Rigid, anxiety 
‘Routine 
driven’ 
Rigid, anxiety  Quiet anxiety ADHD, anxiety ADHD, 
aggressive 
Affinity for 
water, sensitive 
to loud noises 
ADHD, tics - Hand 
flapping 
Hyperactivity, 
short 
attention 
span 
Talks loudly 
Dysmorphism + + + + + + + + + + + + + + 
Coarse features - - + + + +   + +  + + + 
Ectodermal 
features 
TNHP (all) 
blonde 
blonde TNHP (3,4,5) 
blonde 
FNHP 
blonde 
TNHP (2) blonde - TNHP (all) nk blonde blonde nk FNHP(5), TNHP 
(5) 
blonde 
Delayed dental 
eruption 
FNHP (all) 
TNHP 
(especially 
5th) 
TNHP 
 Hand, foot  & 
digital anomalies 
- - - Short toes 5th finger& 
2nd toe HDP 
-  nk nk nk nk Small hands, 
tapering 
fingers, small 
feet  
 HDP, 
tapering 
fingers, 
clinodactyly 
Brachymesop
halangia 
clinodactyly 
Additional 
features 
Laryngomalacia, 
feeding diff, 
constipation 
 Hypotonia, raised 
CPK, constipation 
Alternating 
strabismus 
Webbed neck, 
Wormian 
bones, ?MED 
on skel survey 
Ptosis 
Mixed refractive 
errors 
JH 
Pes cavus, JH, 
myopia 
Hypotonia, PC, 
kyphosis, lordosis, 
DP, laryngeal web, 
CST, dislocatable 
hips at birth 
Wormian 
bones, 
kyphoscoliosis 
- Plagiocephaly Wormian 
bones , 
plagiocephal
y, mild 
pectus 
excavatum 
Seizures  
Bilateral 
inguinal hernia, 
Bilateral 
hyperopia 
Constipation
,Umbilical 
hernia 
 
Cleft palate, diaphragmatic eventration, atrial septal defect in 1/4  
Brain MRI ND ND Delayed 
myelination, 
abnormal CC 
ND ND ND nk Prominent lateral ventricles; small arachnoid cyst 
Mild periventricular leukomalacia  
Dandy-Walker 
malformation  
ND nk 
Other diagnoses 
considered 
 Myotonic dystrophy PTEN 
RASopathy 
Noonan, PKS, 
SLO 
       Mucopolysacc
haridosis 
NPD 
CLS 
FGFR3 SRS 
Other variants 
identified 
  Compound 
het 
missense 
variant in 
VDR 
 Mat missense 
variant FGD1 
 Mat 7q11.23 gain  11q21.1 dup 
(421kb, 
inheritance 
undetermin
ed) 
 EP300 (de 
novo, 
p.Y629N) 
TRIM8 de novo 
c.1333c>t; 
p.Gln445* 
  
ADHD-attention deficit hyperactivity disorder; AFP-alphafetoprotein, CC-corpus callosum; CLS-Coffin-Lowry syndrome; CPK- creatine phosphokinase; CST-cerebral sinus thrombosis; Dec FM-decreased fetal movements; DP-delayed puberty; F-female; FNHP-fingernail hypoplasia; HDP- 
hypoplastic distal phalanges;JH-joint hypermobility; M- male; Mat- maternally inherited; MED- multiple epiphyseal dysplasia; ND- not done; nk-not known; NPD-Niemann-Pick disease; NT-nuchal translucency; PC-pectus carinatum; PH-polyhydramnios; PKS-Pallister Killian syndrome; SD- 
standard deviation; SLO- Smith Lemli Opitz syndrome; SRS- Silver-Russel syndrome; TNHP-toenail hypoplasia,  

